

Application Number 10/574048
Response to Office Action dated 12/10/2007

REMARKS

Favorable reconsideration of this application is requested in view of the following remarks.

Non-elected claims 2, 14, and 20-25 have been canceled without traverse; claims 13 and 15 have been amended to exclude descriptions of the non-elected subject matter.

Claim 18 and 19 have been amended in response to the Examiner's suggestions in the Office Action of December 10, 2007.

Claims 1, 3-13 and 15-19 have been objected to for containing non-elected subject matter. Applicants respectfully traverse this objection.


Claims 13 and 15 have been amended to exclude "a prodrug" or "claim 2". Accordingly, claims 16-19 do not include the non-elected subject matter. In addition, claims 1, 3-12 have been limited to Formula (I) compounds, which are the elected subject matter of the present invention, and these claims do not include a prodrug of Formula (I) or refer to canceled claim 2, a method for inhibition, a method of prevention or treatment or use of the compounds. Therefore, this objection should be withdrawn.

Claims 18 and 19 have been rejected under 35 U.S.C. 112, first paragraph as failing to comply with the enablement requirement. Applicants respectfully traverse this rejection.

The indicated uses in claims 18 and 19 have been amended to pursuant to the Examiner's suggestions. Therefore, this rejection is moot and should be withdrawn. Applicants do not concede correctness of the rejection. Applicants respectfully note that the 35 U.S.C. 112 issue was not relevant to generic compound claim 1. Therefore, Applicants respectfully suggest that the full scope of claim 1 should have been examined when the related species was found allowable, and if prior art uses are raised in a further action, that action should be non-final.

Application Number 10/574048
Response to Office Action dated 12/10/2007


In view of the above, Applicants request reconsideration of the application in the form of a Notice of Allowance.



Dated: February 28, 2008

Respectfully submitted,

HAMRE, SCHUMANN, MUELLER &
LARSON, P.C.
P.O. Box 2902
Minneapolis, MN 55402-0902
(612) 455-3800

By: 
Douglas P. Mueller
Reg. No. 30,300

DPM/my/ad